Company intelligence / Profile preview

Irrimax

Lawrenceville, Georgia, United Statesirrisept.com ↗

Ownership: Private
Development stage: Commercial

Overview

Irrimax’s flagship product, Irrisept Antimicrobial Wound Lavage, is FDA-cleared and used in over 4,000 U.S. hospitals. It contains 0.05% chlorhexidine gluconate for broad-spectrum antimicrobial activity. Clinical data include extensive safety testing with in-vivo/in-vitro studies and randomized controlled trial data showing no systemic toxicity or significant local effects.

Therapeutic areas: OtherDermatologyInfectious Diseases
Modalities: Device (specifically, wound irrigation/antimicrobial lavage device)
Industry: Consumable Medical Devices

Drug pipeline

1 asset

Irrisept

Commercial

Indications: Surgical wound infection prevention

Partnerships

Premier healthcare alliance supplier agreementNAMSA Labs for preclinical studies

Beyond the preview

Go deeper on Irrimax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Irrimax.

Explore the full profile